Adtalem Global Education Inc.

Adtalem Global Education Inc. (ATGE) Market Cap

Adtalem Global Education Inc. has a market capitalization of .

No quote data available.

CEO: Stephen W. Beard

Sector: Consumer Defensive

Industry: Education & Training Services

IPO Date: 1991-06-21

Website: https://www.covista.com

Adtalem Global Education Inc. (ATGE) - Company Information

Market Cap: -|Sector: Consumer Defensive

Company Profile

Adtalem Global Education Inc. is a global enterprise dedicated to delivering comprehensive workforce and educational solutions. Established in 1987 and headquartered in Chicago, Illinois, the company was formerly known as DeVry Education Group Inc. until its name change in May 2017. The organization operates through three distinct segments: 1. Chamberlain: This division offers both academic degree programs and specialized non-degree coursework within the nursing and health professions postsecondary education sector, primarily facilitated by Chamberlain University. 2. Walden: Focused on online learning, the Walden segment provides a wide array of qualifications, from certificates and bachelor's degrees to master's and doctoral programs. These offerings, delivered via Walden University, span numerous fields including nursing, education, counseling, business, psychology, public health, social work, human services, public administration, public policy, and criminal justice. 3. Medical and Veterinary: This segment is committed to postsecondary education in medical and veterinary sciences, furnishing students with both degree and non-degree program options. Its institutions include the American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine.

Analyst Sentiment

92%
Strong Buy

From 2 Active Polls

1Y Forecast: $92.86

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$26

Median

$84

High Bound

$170

Average

$93

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$92.86
▼ -12.92% Upside
Low Target
$26.00
-76% Risk
Median Target
$84.00
-21% Mid
High Target
$170.00
59% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ADTALEM GLOBAL EDUCATION INC (ATGE) — Investment Overview

🧩 Business Model Overview

Adtalem Global Education operates post-secondary education programs delivered through a portfolio of university and professional education brands, with a meaningful emphasis on healthcare and career-focused credentials (including nursing and allied health, as well as medical education and exam-oriented pathways). The business creates value by converting students into enrolled “program participants” and then managing the operational process required to keep them progressing through structured curricula, assessment milestones, and (where relevant) clinical rotations or licensure-prep components.

The model is characterized by an enrollment-to-completion workflow: recruitment and onboarding drive student starts; ongoing term progression produces tuition revenue; and completion/credentialing influences retention, outcomes, and eligibility under regulatory frameworks. Because many programs require uninterrupted participation to reach licensure outcomes, student progress drives customer stickiness and continuity of cash flows.

💰 Revenue Streams & Monetisation Model

Revenue is primarily tuition-based, generated from students who enroll in degree and non-degree programs across terms (typically online and in-person components depending on the program). Monetisation is largely transactional per term (tuition per enrolled student), but with a “cohort continuity” dynamic: students generally remain monetizable across multiple terms until completion, creating a semi-recurring earnings profile tied to retention and course progression.

Margin drivers are operational and program-mix dependent:

  • Enrollment scale and capacity utilization: higher student throughput can leverage fixed instructional and administrative costs.
  • Program mix: healthcare and professional pathways often support pricing power relative to broader academic offerings, but require investment in compliance and student services.
  • Student services efficiency: advising, outcomes support, and retention initiatives affect net revenue through persistence and reduced attrition.
  • Regulatory and aid eligibility effects: federal student aid rules influence effective demand and revenue recognition dynamics.

🧠 Competitive Advantages & Market Positioning

ATGE’s competitive position is anchored in moats that are difficult to replicate quickly due to regulatory accreditation requirements, licensure-linked outcomes, and operational capabilities.

  • Regulatory moat (accreditation & program approval barriers): Educational providers must satisfy accreditation standards and maintain eligibility for student aid. Developing compliant programs, hiring credentialed faculty, and meeting oversight requirements creates a high barrier to entry for new entrants and limits “fast-follow” competitive disruption.
  • Switching costs via credential progression: Students typically commit to structured pathways with accumulated credits and progress toward licensure or professional credentialing. Changing providers can forfeit credits, delay completion, or create licensure disadvantages, increasing stickiness within a completed program track.
  • Intangible assets in outcomes and student support: Outcomes performance, advising, and remediation play a disproportionate role in student persistence and institutional compliance. These capabilities are built over time and are difficult to copy without comparable systems and experience.

Competitive benchmarking (industry focus vs peers):

  • Strategic Education (SE) — diversified higher-education offerings with strong online presence (e.g., Capella). ATGE’s emphasis is comparatively more concentrated in healthcare-anchored education and licensure-connected pathways.
  • Grand Canyon Education (GCE) — large-scale education provider with a substantial footprint in teaching and related fields. GCE competes for overlapping online demand pools, while ATGE’s healthcare-centric positioning differentiates program needs and outcome expectations.
  • Kaplan (Graham Holdings) — broad education and test-prep footprint. Kaplan competes strongly on flexibility and program breadth, but ATGE’s regulatory program structure and credential completion model create different switching dynamics for students pursuing licensure-linked healthcare credentials.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is driven less by product “refresh cycles” and more by structural workforce needs and credential demand:

  • Healthcare workforce expansion: persistent demand for nurses, allied health professionals, and medical education capacity increases the addressable market for credential-based providers.
  • Online and hybrid learning penetration: broader acceptance of remote education supports continued student acquisition at scale, while improving geographic accessibility.
  • Credentialing requirements and career mobility: employers and regulatory bodies increasingly align hiring and advancement to recognized credentials, supporting student willingness to progress through established programs.
  • Capacity and program optimization: improving retention, reducing time-to-completion where feasible, and managing instructional utilization can compound over multiple cohorts.

⚠ Risk Factors to Monitor

  • Federal and regulatory risk: Higher-education regulation and changes to student aid eligibility can alter demand, enrollment quality, and revenue durability.
  • Accreditation and outcomes compliance: Failure to meet accreditation standards or outcomes-based oversight can constrain growth, change program structures, or lead to corrective actions.
  • Clinical placement and capacity constraints: Healthcare programs can face bottlenecks in clinical site availability and associated costs, affecting throughput and persistence.
  • Enrollment cycle volatility: Education demand can react to macro conditions, student financing availability, and competitive recruiting intensity.
  • Legal and reputational overhang: Like peers in the sector, institutions are exposed to litigation risk and reputational scrutiny that can influence enrollments and compliance cost.

📊 Valuation & Market View

Equity research coverage for education providers typically frames valuation around operating leverage and regulatory risk rather than near-term “growth optics.” Market participants often monitor:

  • Profitability and cash generation: enterprise value relative to operating earnings and free cash flow capacity tends to guide valuation, especially where earnings quality is supported by stable retention and cohort persistence.
  • Enrollment and persistence metrics: the market generally rewards durability of student progression and demand quality, which affects both revenue and compliance outcomes.
  • Regulatory risk premium: changes to federal aid, accreditation standards, or outcomes-based rules can expand or contract multiples by changing perceived earnings stability.

In practice, sector valuation typically trends with EV/EBITDA or P/S (as investors price growth and the risk-adjusted durability of tuition receipts), with key variable drivers being enrollment stability, margin trajectory, and regulatory visibility.

🔍 Investment Takeaway

ATGE presents a long-term thesis grounded in healthcare-tilted credential demand, supported by moats formed through regulatory accreditation barriers, student switching costs tied to program progression, and operational know-how in outcomes-focused student support. The investment case depends on maintaining compliance strength and enrollment persistence while navigating regulatory and capacity risks inherent to post-secondary education.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"ATGE (2026-03-31) reported Revenue of $487.0M and Net Income of $42.6M, with EPS of $1.19 (basic) and $1.67 (diluted). QoQ, Revenue declined from $503.4M (2025-12-31) to $487.0M (down ~3.3%), while Net Income also fell from $76.4M to $42.6M (down ~44.2%). YoY, Revenue increased from $466.1M (2025-03-31) to $487.0M (up ~4.5%), and Net Income rose from $60.8M to $42.6M (down ~30.0%), indicating profit pressure despite modest top-line growth. Profitability contracted over the 4-quarter period: gross margin was negative in the most recent quarter (-114.9% gross margin ratio) versus positive ~56–59% in prior quarters, while operating income remained positive at $91.3M but operating margin fell to ~18.8% from ~22.1% in Q2 (and ~19.5% in Q3 prior year). Cash flow quality remained strong: operating cash flow was $186.1M and free cash flow $165.9M in Q3, despite lower net income. Balance sheet leverage increased: total assets rose to ~$2.74B, equity was stable near ~$1.36B, and net debt increased to ~$589M from ~$673M (improved), though total debt remains elevated. Shareholder returns: dividends were $0. The company repurchased stock (common stock repurchased $67.5M), supporting total return, but marketPerformance data (1y_change) is unavailable, so valuation/price-momentum impact could not be scored."

Revenue Growth

Neutral

QoQ revenue decreased ~3.3% (503.4M to 487.0M) but YoY revenue increased ~4.5% (466.1M to 487.0M).

Profitability

Neutral

Net income fell ~44.2% QoQ and ~30.0% YoY. Operating margin declined to ~18.8% from ~22.1% (Q2). Gross profit ratio turned sharply negative in the latest quarter (-114.9%), signaling severe gross-level pressure or classification volatility.

Cash Flow Quality

Positive

Operating cash flow improved to $186.1M and free cash flow was $165.9M in the latest quarter, indicating solid cash conversion despite lower reported net income.

Leverage & Balance Sheet

Fair

Total assets increased to ~$2.74B. Equity remains stable around ~$1.36B. Net debt improved to ~$589M from ~$673M QoQ, though total debt remains substantial (~$736M).

Shareholder Returns

Fair

No dividends. Buybacks continued (repurchased ~$67.5M in the latest quarter), supporting capital return, but total shareholder return cannot be fully quantified due to missing marketPerformance (1y_change undefined).

Analyst Sentiment & Valuation

Caution

Valuation sentiment is hard to gauge: current price is not provided (marketPerformance shows price=0 and 1y_change undefined). Provided consensus price target is $138, but upside/downside vs current share price cannot be calculated from the dataset.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

ATGE’s (transcript actually for Covista) Q3 2026 shows improving operating execution translating into margin expansion and upward guidance. Revenue grew 4.5% to $487M, but management attributed volatility largely to a Walden calendar timing shift (1 week; $18M revenue moved into Q2). On a like-for-like basis, consolidated revenue growth would be 8.4%, with adjusted EBITDA margin up 150 bps to 28.9%. Segment performance is the driver: Walden margin +280 bps and Med/vet +250 bps, while Chamberlain’s return to positive enrollment growth (total enrollment +0.5% and record-high) came after targeted fixes to marketing effectiveness and funnel conversion. Capital allocation remains disciplined—$66M repurchase, $510M Term Loan B refinanced with 50 bps lower rate to 2033, and net leverage at 0.7x—supporting continued investment (campus expansion and AI platform). FY2026 guidance rises to $1.93B–$1.945B revenue and $7.95–$8.15 EPS, with continued focus on execution into the September fall enrollment cycle.

AI IconGrowth Catalysts

  • Chamberlain operational remediation driving return to positive total enrollment growth: total enrollment +0.5% to 40,767 and “highest enrollment in university history”
  • Chamberlain execution improvements: localized marketing, simplified application experience, rebuilt scholarship process, upgraded talent; funnel conversion up; application volumes improved sharply
  • Walden student persistence initiatives compounding: enrollment +12.3% to 54,474 with first-to-second semester retention discipline expanded deeper
  • Walden new program launches: clinical psychology and behavioral analysis enrolled 1,400+ students; 7 additional programs approved including palliative care and special education
  • Medical & Veterinary operating leverage: enrollment +4.1% to 5,344; adjusted EBITDA margin +250 bps to 26.5%
  • AI credentials traction: 4,000+ learners enrolled in newly launched AI credentials across nursing/medicine/foundational AI; additional certificates launching later in 2026
  • Enterprise AI/learning platform build-out with Google Cloud: AI-powered classroom pilots launching later in 2026

Business Development

  • Named employer partnership: SSM (St. Louis campus interest; increased applications/inquiries; partnership described as thriving; no specific deal terms disclosed)
  • Employer/provider partnership pipeline: “several conversations active around the country” with expectation to announce new partnerships “in the near term”
  • Technology partner: Google Cloud (codeveloping AI-powered classroom and enrolling 4,000+ learners in AI credentials)

AI IconFinancial Highlights

  • Revenue: $487M +4.5% YoY; Walden 1-week calendar shift moved $18M revenue from Q3 to Q2
  • Organic trajectory: excluding the 1-week timing impact, consolidated revenue would have increased 8.4% YoY
  • Adjusted EBITDA: $127.9M; excluding timing, would have been $145.9M (+14.2% YoY) with adjusted EBITDA margin 28.9% (+150 bps YoY)
  • Adjusted operating income: $102.2M; excluding timing, would have been $120.3M (+14.1% YoY) with partial offset from strategic growth investments
  • Adjusted EPS: $1.98 (impacted by Walden calendar shift)
  • Segment margins: Chamberlain adjusted EBITDA margin 29.7% (+20 bps YoY); Walden adjusted EBITDA margin 33.1% (+280 bps YoY); Med/vet adjusted EBITDA margin 26.5% (+250 bps YoY)
  • Capital structure: 50 bps rate reduction on refinanced long-term debt and maturity extended to 2033; ended quarter net leverage 0.7x
  • Guidance raise: FY2026 revenue now $1.93B–$1.945B (from $1.9B–$1.94B); adjusted EPS now $7.95–$8.15 (from $7.80–$8.0)
  • Guidance implies FY2026 adjusted EPS growth of 19%–22% YoY; management continues to target expanding FY2026 adjusted EBITDA margin by +100 bps
  • Tax: management expects effective tax rate higher than FY2025 (no further numeric provided)

AI IconCapital Funding

  • Share repurchases: $66M during the quarter
  • Debt refinancing: consolidated into $510M Term Loan B; 50 bps rate improvement; extended maturity to 2033
  • Liquidity: cash and equivalents $147M as of March 31, 2026
  • Net leverage: 0.7x ended the quarter
  • Trailing 12-month free cash flow: $336M (+17% YoY), cited as supporting multiple capital-allocation paths

AI IconStrategy & Ops

  • Chamberlain application review time cut by weeks via process improvements and workflow automation
  • Operational model changes implemented at Chamberlain: localized marketing, simplified application experience, rebuilt scholarship process, and staffing upgrades in critical enrollment roles
  • Campus expansion: 6 new campuses in active development; 1 begins teaching in September; 2 received full regulatory approval since Investor Day
  • Leadership additions: Amelia Manning to join Chamberlain as next President; Michael Betz takes expanded role as Chief Growth and Innovation Officer with marketing oversight added to Walden/digital work

AI IconMarket Outlook

  • FY2026 revenue guidance: $1.93B–$1.945B
  • FY2026 adjusted EPS guidance: $7.95–$8.15
  • Q4 enrollment outlook at Chamberlain: management expects Q4 to look like Q3 with momentum building into the fall enrollment cycle (clarified in Q&A as “rate of growth directionally similar,” not same absolute enrollment)
  • 2026 Q4 financial profile: CFO expects Q4 CapEx ramp above Q3; management stated no “push out” of expenses from Q3 into Q4 via timing—investments are incremental via dynamic resource allocation

AI IconRisks & Headwinds

  • Walden timing risk: 1 academic week shift can materially impact Q/Q revenue and margin comparability (explicitly $18M revenue impact and meaningful margin profile impact)
  • Execution risk at Chamberlain acknowledged previously (marketing effectiveness and funnel conversion failure) though now described as remediated; continued dependency on conversion normalization into fall cycle
  • Higher effective tax rate expected vs FY2025 (could pressure earnings vs prior year)
  • Ongoing need to fund strategic growth investments in Q4 while still expanding margins (margin expansion targets require execution)

Q&A: Analyst Interest

  • SSM and partnership progress: Management said SSM “continues to thrive,” citing increased applications/inquiries around the St. Louis campus. They provided no deal specifics but framed SSM as a “proof point” for differentiated healthcare talent acquisition, and noted multiple active national conversations with possible near-term announcements.
  • Expense timing vs run-rate investments: CFO stated there was “no” shift of expenses from Q3 into Q4. Management described a “dynamic resource allocation model,” emphasizing incremental fourth-quarter investments rather than timing deferrals, implying CapEx/OpEx ramp is planned for business reasons rather than accounting artifacts.
  • Chamberlain Q4 campaign/conversion focus: Management emphasized execution discipline: Chamberlain has strong nursing brand equity and program mix, and the prior fall enrollment cycle was treated as an anomaly. They highlighted leadership change (new President starting imminently) and expect “rate of growth directionally similar” into the September 2026 enrollment cycle.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the ATGE Q3 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — Adtalem Global Education Inc. (ATGE) Financial Profile